个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhong Kaili[1] * ; Shi Yanyan[2] * ; Gao Yuhuan[3] ; Zhang Huilai[4] ; Zhang Mingzhi[5] ; Zhang Qiaohua[6] ; Cen Xinan[7] ; Xue Mei[8] ; Qin Yan[9] ; Zhao Yu[10] ; Zhang Liling[11] ; Liang Rong[12] ; Wang Ningju[13] ; Xie Yan[14] ; Yang Yu[15] ; Liu Aichun[16] ; Bao Huizheng[17] ; Wang Jingwen[18] ; Cao Baoping[1] ; Zhang Wei[19] ; Zhang Weijing[1] ;
机构： [1]Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. [2]Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China. [3]Department of Hematology, Fourth Hospital of Hebei Medical University (Tumor Hospital of Hebei Province), Shijiazhuang, China. [4]Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [5]Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. [6]Departmentof Oncology, Shanxi Academy of Medical Sciences & Shanxi Bethune Hospital, Shanxi Bethune Hospital affiliated to Shanxi Medical University, Taiyuan, China. [7]Department of Hematology, Peking University First Hospital, Beijing, China. [8]Department of Hematology, Air Force Medical Center, Beijing, China. [9]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. [10]Department of Hematology, the General Hospital of PLA, Beijing, China. [11]Department of Lymphoma, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [12]Department of Hematology, Xijing Hospital, Air Force Military Medical University, Xi’an, China. [13]Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China. [14]Departments of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China. [15]Department of Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China. [16]Department of Hematology and Lymphoma, Cancer hospital of Harbin Medical University, Haerbin, China. [17]Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China. [18]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. [19]Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
出处：
DOI： 10.1186/s12885-023-11268-5
ISSN：

关键词： First-line induction chemotherapy Methotrexate Primary central nervous system lymphoma Teniposide

摘要：
This study aimed to compare the efficacy and safety of high-dose methotrexate (HD-MTX) versus teniposide (TEN) in patients with newly diagnosed immunocompetent primary central nervous system lymphomas (PCNSLs).The study included immunocompetent, adult patients with newly diagnosed PCNSL at 22 centers in China from 2007 to 2016. The patients received HD-MTX or TEN as first-line induction therapy. The objective response rate, progression-free survival, and overall survival were analyzed for each patient cohort.A total of 96 patients were eligible: 62 received HD-MTX, while 34 received teniposide. The overall response rate was 73.2% and 72.7% in the MTX and the TEN cohorts, respectively (P = 0.627). The median progression-free survival was 28.4 months [95% confidence interval (CI): 13.7-51.2] in the MTX cohort and 24.3 months (95% CI: 16.6-32.1) in the TEN cohort (P = 0.75). The median overall survival was 31 months (95% CI: 26.8-35.2) in the MTX cohort and 32 months (95% CI: 27.6-36.4) in the TEN cohort (P = 0.77). The incidence of any grade of coagulopathy/deep-vein thrombosis and gastrointestinal disorders was significantly higher in the MTX cohort than in the TEN cohort; no significant difference was found in the incidence of other adverse events between the two cohorts.This was the first multicenter study using TEN as the main agent compared with HD-MTX in newly diagnosed primary CNS lymphoma. The TEN-based regimen was non-inferior to the HD-MTX-based regimen with similar overall responses.This study provided Class III evidence that the teniposide-based regimen was non-inferior to high-dose methotrexate - based regimen with similar overall responses and long-time survival in immunocompetent patients with PCNSL.© 2023. BioMed Central Ltd., part of Springer Nature.

基金：
This work was supported by the Research and Cultivation Fund of Capital Medical University (PYZ21157); Institutional Grant of Beijing Shijitan Hospital, Capital Medical University (2017-c04); Capital’s Funds for Health Improvement and Research (2018–1-2151).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhong Kaili,Shi Yanyan,Gao Yuhuan,et al.First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study[J].BMC CANCER.2023,23(1):doi:10.1186/s12885-023-11268-5.
APA：
Zhong Kaili,Shi Yanyan,Gao Yuhuan,Zhang Huilai,Zhang Mingzhi...&Zhang Weijing.(2023).First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.BMC CANCER,23,(1)
MLA：
Zhong Kaili,et al."First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study".BMC CANCER 23..1(2023)

相关文献

[1]Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker [2]31例原发性中枢神经系统恶性淋巴瘤临床分析 [3]31例原发性中枢神经系统恶性淋巴瘤临床分析 [4]原发性中枢神经系统淋巴瘤的特点及诊治的研究进展 [5]31例原发性中枢神经系统恶性淋巴瘤临床分析 [6]First-line induction or consolidation chemotherapy combined with concurrent chemoradiotherapy for esophageal squamous cell carcinoma [7]A Validated HPLC-MS/MS Method for Quantification of Methotrexate and Application for Therapeutic Drug Monitoring in Children and Adults with Non-Hodgkin Lymphoma [8]单用替莫唑胺与替尼泊甙联合洛莫司汀治疗恶性胶质瘤的比较 [9]Development, validation, and application of an UPLC-MS/MS method for vancomycin, norvancomycin, methotrexate, paclitaxel, and imatinib analysis in human plasma. [10]VEP-M在视觉通路病变中的应用价值(附18例报道)

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号